Press Releases for RDY

Press Releases
AMRI Announces Third Quarter 2009 Results
Dr. Reddy's Q2 FY10 Results
Ceragenix and MEGAPHARM Enter Into Distribution and Supply Agreement for EpiCeram®
Dr. Reddy’s Q1 FY10 Results
Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddy’s Announces Strategic Alliance with GSK for Emerging Markets
Dr. Reddy’s Announces ANDA Approval of Omeprazole Mg OTC
Dr. Reddy’s Receives Approval for Three INDs and Announces Reorganization of Its Drug Discovery Operations
Ceragenix Enters into Second Exclusive Option to License Agreement for Antimicrobial Medical Device
Dr. Reddy’s Laboratories Realigns Global Generics Geography Portfolio
Dr. Reddy’s Crosses $150 Million Revenue Milestone in Russia & CIS Region
Dr. Reddy's Receives Favorable Summary Judgment Ruling in the Omeprazole Mg OTC Litigation
Dr. Reddy’s Receives Favorable Summary Judgment Ruling in the Omeprazole Mg OTC Litigation
Zacks Analyst Blog Highlights: Ladish, Banco Santander Central Hispano, S.A., Dr. Reddy's Laboratories, Ltd., Tesoro Corporation and UBS AG.
Dr. Reddy’s Announces Five ANDA Approvals and Generic Product Launches in the US Market
Dr. Reddy’s Q3 FY09 Revenue at Rs. 18,401 million, EBITDA at Rs. 3,453 million, PAT at Rs. 1,924 million
Dr. Reddy's to Release Q3 FY09 Results on January 20, 2009; Earnings Call Slated for January 20, 6.30 PM IST/8.00 AM EST
Dr. Reddy’s Announces the Appointment of New Chief Financial Officer (CFO)
Dr. Reddy’s Laboratories Announce Settlement of Clarinex® (Desloratadine) ANDA Patent litigation With Schering Corporation and Sepracor Inc.
Dr. Reddy’s (betapharm) Receives Preliminary Results on AOK Tender in Germany
Dr. Reddy’s Launches Authorized Generic Version of Imitrex®* Tablets
Dr. Reddy's Q2 FY09 Revenue at Rs. 16,151 Million, EBITDA at Rs. 2,746 Million, PAT at Rs. 1,212 Million
Promius Pharma, LLC Launches EpiCeram(R) Skin Barrier Emulsion - Oct 14 2008 8:34AM
Dr. Reddy's Wholly-Owned Subsidiary Promius Pharma Launches EPICERAM(R) Skin Barrier Emulsion
Promius Pharma, LLC Launches EpiCeram(R) Skin Barrier Emulsion - Oct 14 2008 6:15AM
Dr. Reddy's to Release Q2 FY09 Results on October 23, 2008; Earnings Call Slated for October 23, 6.30 PM IST/9.00 AM EST
Dr. Reddy's Formally Announces its US Specialty Business, Promius Pharma, LLC.
CORRECTING and REPLACING Cosmederm Technologies Announces Partnership with Dr. Reddy's for Indian Distribution of Proprietary Skin Care Products
Cosmederm Technologies Announces Partnership with Dr. Reddy's for Indian Distribution of Proprietary Skin Care Products
Dr. Reddy's Q1 FY09 Revenue at Rs. 15,038 Million; EBITDA at Rs. 2,710 Million, PAT at Rs. 1,346 Million
Dr. Reddy's Annual Report on Form 20-F for Year Ended March 31, 2008 Available on the Company's Website
Dr. Reddy's To Release Q1 FY09 Results on July 21, 2008; Earnings Call Slated for July 21, 6.30 PM IST/9.00 AM EST
Dr. Reddy's Releases Annual Report for Fiscal 2007-08
Dr. Reddy's FY08 Revenue at Rs. 50,006 Million; EBITDA at Rs. 9,736 Million - May 27 2008 12:57AM
Dr. Reddy's to release FY08 results on May 20, 2008 - Jun 2 2008 2:37AM
Dr. Reddy's Announces the Completion of Two Acquisitions - Jun 2 2008 2:37AM
Dr. Reddy's Acquires BASF's Pharmaceutical Contract Manufacturing Business and Related Facility at Shreveport in the US
Dr. Reddy's Acquires Jet Generici Srl
Dr. Reddy's Signs Definitive Agreement to Acquire Dowpharma Small Molecules Business Associated with Dow's Mirfield and Cambridge, UK Sites